Walter J. Curran Jr., M.D.

Emory University
Recruited: 2012

Walter Curran takes on patients with some of the toughest cancers out there: locally advanced lung cancer and malignant brain tumors. Patients diagnosed with either of these cancers often survive less than two years.

An internationally renowned radiation oncologist, Curran has led landmark clinical and translational trials for both groups of patients. He continues to develop and conduct trials to see how new approaches with radiation, surgery and drug therapies can slow or stop these killers.
Curran is among the nation’s top-funded cancer investigators, awarded millions in research grants from the National Cancer Institute (NCI). He also serves as executive director of the Winship Cancer Institute of Emory University, leading the charge to find cures for not only these deadliest cancers, but many others as well. He also serves as one of the leaders of the new NCI-funded network group, NRG Oncology.


Curran’s current clinical trials include:

  • Phase I study of whole brain radiation therapy with simultaneous boost to gross metastatic tumor volume using RapidArc (cancer type: metastases)
  • Phase I trial of stereotactic radiosurgery following surgical resection of intra-axial brain metastases (cancer type: metastases)
  • Phase III randomized study of three different thoracic radiotherapy regimens in patients with limited-stage small cell lung cancer receiving cisplatin and etoposide (cancer type: lung cancer)
  • Phase II randomized study of prophylactic cranial irradiation, with vs. without consolidative extracranial radiotherapy in patients with extensive stage small cell lung cancer (cancer type: lung cancer)
  • Phase II/III randomized study of image-guided radiosurgery or stereotactic body radiotherapy in patients with localized spine metastasis (cancer type: metastases)
  • Phase III randomized study of radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma (cancer type: brain cancer)
  • Phase III randomized study of radiotherapy, with vs. without temozolomide in patients with symptomatic or progressive low-grade gliomas (cancer type: brain cancer)
  • Phase I trial of ganetespib, capecitabine, and radiation in rectal cancer (cancer type: colon/rectal cancer)


Choosing Georgia

Prior to joining Emory and Winship, Curran was clinical director of the Kimmel Cancer Center at Jefferson Medical College in Philadelphia, where he also was chairman of the department of radiation oncology. He came to Emory to work with its “tremendous faculty and staff,” and to join in its efforts in both research and patient care.